Australia's PolyNovo jumps on positive results from its diabetes therapy trial

Polynovo

13/05/2025 06:01

** PolyNovo PNV.AX jumps as much as 14.7% to A$1.675; marks biggest intraday pct rise since June 7, 2023

** Stock among top gainers on benchmark ASX200 index .AXJO

** Medical devices maker announces positive results from its NovoSorb BTM treatment in managing Type 1 diabetes

** Says proof-of-concept study showed survival and function of human pancreatic islets transplanted into alternative neovascularised site within the skin using NovoSorb BTM

** PNV last up 10.3%, trims YTD losses to ~19.2%

 (Reporting by Kumar Tanishk in Bengaluru)

 ((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk;))